Statin and cholesterol absorption inhibitor combination

This page covers all Statin and cholesterol absorption inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HMG-CoA reductase and NPC1L1 transporter, HMG-CoA reductase; NPC1L1 transporter, HMG-CoA reductase (simvastatin); Niemann-Pick C1-like 1 protein (ezetimibe).

Targets

HMG-CoA reductase and NPC1L1 transporter · HMG-CoA reductase; NPC1L1 transporter · HMG-CoA reductase (simvastatin); Niemann-Pick C1-like 1 protein (ezetimibe) · ACAT2 and NPC1L1

Marketed (5)

• simvastatin and ezetimibe · UMC Utrecht · Cardiovascular
  Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.
• Atorvastatin, Ezetimibe · Abant Izzet Baysal University · Cardiovascular
  Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.
• atorvastatin plus ezetimibe · Shanghai Jiao Tong University School of Medicine · Cardiovascular
  Atorvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels through dual pathways.
• statins, ezetimibe · Korea University Anam Hospital · Cardiovascular
  Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis, while ezetimibe blocks intestinal cholesterol absorption, together lowering LDL cholesterol levels.
• Fixed combination simvastatin/ezetimibe · Novartis · Cardiovascular
  This combination reduces cholesterol by blocking its synthesis in the liver (simvastatin) and inhibiting its absorption in the intestines (ezetimibe).

Phase 3 pipeline (1)

• Lapaquistat acetate and ezetimibe · Takeda · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.

Patent intelligence

• cholesterol absorption inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates